99 filings
Page 2 of 5
PRE 14A
9p0ifu 4nm4fp13ho
10 Apr 23
Preliminary proxy
4:31pm
8-K
ajpe46mp
10 Apr 23
Departure of Directors or Certain Officers
4:30pm
8-K
no9ib
18 Jan 23
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
4:36pm
8-K
h5tm8nvaew8bu
6 Dec 22
Designation Represents Potential to Bring Important New Therapy to Patients Earlier
4:23pm
8-K
r8492l
30 Nov 22
Cost Associated with Exit or Disposal Activities
4:32pm
8-K
usqjfdxt5l60 1iyz
6 Sep 22
SQZ Biotechnologies Announces Leadership Transition
4:33pm
8-K
06gbdsy
11 Jul 22
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
4:49pm
8-K
w0f ei00is6
16 Jun 22
Submission of Matters to a Vote of Security Holders
8:19am
8-K
z43k6ywjsktbb
31 May 22
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease
4:52pm
8-K
5gfy elb8hzb
19 May 22
Regulation FD Disclosure
4:05pm
DEFA14A
bojw7
26 Apr 22
Additional proxy soliciting materials
5:08pm
8-K
4fh a51k8hgks52o
24 Jan 22
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
7:01am
8-K
cyx pmv2k7cko
9 Dec 21
Other Events
7:30am
8-K
7bvdqfqnb t4
2 Dec 21
Other Events
6:28am